1056 Feasibility and ultility of cardiac MRI in patients with valved bovine jugular vein conduits for right ventricular
- PDF / 288,278 Bytes
- 2 Pages / 610 x 792 pts Page_size
- 11 Downloads / 183 Views
BioMed Central
Open Access
Meeting abstract
1056 Feasibility and ultility of cardiac MRI in patients with valved bovine jugular vein conduits for right ventricular outflow tract reconstruction Sabeena Ramrakhiani*1, Mervyn D Cohen2, John W Brown3 and Tiffanie R Johnson4 Address: 1Krannert Institute of Cardiology, Indianapolis, IN, USA, 2Department of Radiology, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, USA, 3Department of Cardiothoracic Surgery, Indiana University School of Medicine, Indianapolis, IN, USA and 4Indiana University, Riley hospital for Children, Section of Pediatric Cardiology, Indianapolis, IN, USA * Corresponding author
from 11th Annual SCMR Scientific Sessions Los Angeles, CA, USA. 1–3 February 2008 Published: 22 October 2008 Journal of Cardiovascular Magnetic Resonance 2008, 10(Suppl 1):A181
doi:10.1186/1532-429X-10-S1-A181
Abstracts of the 11th Annual SCMR Scientific Sessions - 2008
Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1532-429X-10-S1-info.pdfThis abstract is available from: http://jcmr-online.com/content/10/S1/A181 © 2008 Ramrakhiani et al; licensee BioMed Central Ltd.
Background Pulmonary homografts have been the most widely used valved conduits for right ventricular outflow tract (RVOT) reconstruction in the US since mid 1980s. In 1999 a conduit containing a bovine jugular vein (Contegra®, Medtronic, Inc, Minneapolis, MN) was introduced as a potential alternative for RVOT reconstruction. In 2003, the bovine jugular vein conduit was released by the FDA for humanitarian device exemption (HDE) utilization in centers that obtain institutional review board approval and have appropriate informed patient consent. Main advantages of the Contegra® conduit include availability in sizes from 12–22 mm, natural continuity between the valve and the conduit that allows proximal infundibular shaping without additional materials, lower price compared to about half of the pulmonary homografts in the US, and reduced potential risk of supravalvular stenosis due to narrowing at the distal suture line. This data has been reported based on echocardiographic findings of the Contegra® conduit postoperatively. We report on the use of cardiac magnetic resonance (CMR) in patients postoperatively and compare the findings with echocardiography.
Methods We retrospectively analyzed the results of CMR performed pre- and postoperatively in 5 patients with the Contegra®
conduit. CMR was performed using a 1.5 Tesla Siemens Avanto system (Siemens Medical solutions, Malvern, PA). Standard images for anatomical and functional evaluation, including volume and flow analysis were reviewed. Descriptive statistical analysis was performed.
Results The mean age of patients was 20.2 years with average weight 116.7 lbs and body surface area of 1.57 sq meters. There were 4 males and 1 female. Primary pathologies included tetralogy of Fallot (n = 3), double outlet right ventricle w
Data Loading...
